news articles
-
‘RevoAb™’: A New Service for Antibody Developability Engineering
-
RevolKa Ltd. Joins Research and Development Program for Innovative Biologics Funded by the Japanese Agency for Medical Research and Development (AMED)
-
RevolKa Ltd. Secures 210 million JPY (US$1.4 million) Series A Extension Funding to Advance Therapeutic Programs
-
RevolKa’s corporate website has been renewed
-
RevolKa has been selected as a member of the Google for Startups Cloud Program.
-
Our advertisement feature was published in the online version of Nature
-
Concluded a joint research agreement with Sumitomo Dainippon Pharma